Literature DB >> 16939428

Review article: the role of bile and pepsin in the pathophysiology and treatment of gastro-oesophageal reflux disease.

J Tack1.   

Abstract

Gastro-oesophageal reflux disease is a multifaceted and multifactorial disorder which results from the reflux of gastric contents into the oesophagus. Animal studies suggest that synergism between acid and pepsin and conjugated bile acids have the greatest damaging potential for oesophageal mucosa, although unconjugated bile acids may be caustic at more neutral pH. Human studies are compatible with a synergistic action between acid and duodenogastric reflux in inducing lesions. During prolonged monitoring studies, typical gastro-oesophageal reflux symptoms are more related to acid reflux events than to non-acid reflux events. However, symptoms that persist during acid suppressive therapy are often related to non-acid reflux events. The therapeutic options for the non-acid component of the refluxate, including acid suppression, prokinetics, baclofen, surgery and mucosal protective agents like alginates, are discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16939428     DOI: 10.1111/j.1365-2036.2006.03040.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  13 in total

1.  Alginates: From the ocean to gastroesophageal reflux disease treatment.

Authors:  Serhat Bor; İsmail Hakkı Kalkan; Altay Çelebi; Dinç Dinçer; Filiz Akyüz; Peter Dettmar; Hasan Özen
Journal:  Turk J Gastroenterol       Date:  2019-09       Impact factor: 1.852

2.  Histamine regulation of hyperplastic and neoplastic cell growth in cholangiocytes.

Authors:  Paolo Onori; Eugenio Gaudio; Antonio Franchitto; Gianfranco Alpini; Heather Francis
Journal:  World J Gastrointest Pathophysiol       Date:  2010-06-15

3.  Non-erosive reflux disease (NERD), symptomatic and asymptomatic erosive reflux disease (ERD): from hypersensitive to hyposensitive esophagus.

Authors:  Juanda L Hartono; Choon-Seng Qua; Khean-Lee Goh
Journal:  Dig Dis Sci       Date:  2010-05-14       Impact factor: 3.199

4.  Biliary hyperkinesia in adolescents-it isn't all hype!

Authors:  Maggie E Bosley; Jillian Jacobson; Michaela W G Gaffley; Michael A Beckwith; Samir R Pandya; James S Davis; Lucas P Neff
Journal:  Transl Gastroenterol Hepatol       Date:  2021-07-25

5.  Characteristics of the Human Upper Gastrointestinal Contents in the Fasted State Under Hypo- and A-chlorhydric Gastric Conditions Under Conditions of Typical Drug - Drug Interaction Studies.

Authors:  Chara Litou; Maria Vertzoni; Constantinos Goumas; Vassilis Vasdekis; Wei Xu; Filippos Kesisoglou; Christos Reppas
Journal:  Pharm Res       Date:  2016-03-14       Impact factor: 4.200

6.  The value of a liquid alginate suspension (Gaviscon Advance) in the management of laryngopharyngeal reflux.

Authors:  Julian A McGlashan; Lesley M Johnstone; John Sykes; Vicki Strugala; Peter W Dettmar
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-05-28       Impact factor: 2.503

Review 7.  Strategy for treatment of nonerosive reflux disease in Asia.

Authors:  Toru Hiyama; Masaharu Yoshihara; Shinji Tanaka; Ken Haruma; Kazuaki Chayama
Journal:  World J Gastroenterol       Date:  2008-05-28       Impact factor: 5.742

8.  Bile acids repress hypoxia-inducible factor 1 signaling and modulate the airway immune response.

Authors:  Claire Legendre; F Jerry Reen; David F Woods; Marlies J Mooij; Claire Adams; Fergal O'Gara
Journal:  Infect Immun       Date:  2014-06-09       Impact factor: 3.441

9.  Yield of 24-hour esophageal pH and bilitec monitoring in patients with persisting symptoms on PPI therapy.

Authors:  George Karamanolis; Tim Vanuytsel; Daniel Sifrim; Raf Bisschops; Joris Arts; Philip Caenepeel; Dominiek Dewulf; Jan Tack
Journal:  Dig Dis Sci       Date:  2008-03-06       Impact factor: 3.199

10.  Orally administered L-arginine and glycine are highly effective against acid reflux esophagitis in rats.

Authors:  Kenji Nagahama; Hikaru Nishio; Masanori Yamato; Koji Takeuchi
Journal:  Med Sci Monit       Date:  2012-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.